Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1

Journal of Clinical Microbiology

Volumn 40, Issue 1, 2002, Pages 31-35

  Qari, S H ^a   Respess, R ^a   Weinstock, H ^a   Beltrami, E M ^a   Hertogs, K ^a   Larder, B A ^a   Petropoulos, C J ^a   Hellmann, N ^a   Heneine, W ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MUTATION; OCCUPATIONAL EXPOSURE; PHENOTYPE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS ISOLATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; REAGENT KITS, DIAGNOSTIC; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0036135675     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.40.1.31-35.2002     Document Type: Article

References (21)

1. Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine
2. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen
3. Comparison of selective polymerase chain reaction primers and differential probe hybridization of polymerase chain reaction products for determination of relative amounts of codon 215 mutant and wild-type HIV-1 populations
4. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting
5. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
6. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
7. Antiretroviral drug resistance testing in adult HIV-1 infection: Recommendations of an International AIDS Society-USA Panel
8. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
9. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates
10. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
11. Reduced susceptibility of human immunodeficiency virus type 1 (HIV-1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites
12. Characterization of HIV isolates arising after prolonged zidovudine therapy
13. HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy
14. Dual resistance to zidovudine and lamivudine in patients treated with zidovudinetamivudine combination therapy
15. Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine
16. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
17. Mutations in retroviral genes associated with drug resistance: 2000-2001 Update
18. A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors
19. Line probe assay for the rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
20. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89
21. Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States. 1993-1998